The Cooper Companies Inc.
Cooper Companies Announces Q4 2025 Financial Results and Leadership Transition
Summary
On December 4, 2025, The Cooper Companies, Inc. reported its fiscal fourth quarter and full-year 2025 financial results, highlighting a 5% revenue increase to $1,065.2 million in Q4 and $4.1 billion for the full year. GAAP diluted EPS decreased by 27% in Q4 and 4% for the full year, while non-GAAP diluted EPS improved by 11% and 12% respectively. The company also announced that Robert S. Weiss, Chairman, will resign effective January 2, 2026, and Colleen E. Jay will succeed him. The company expanded its share repurchase program by $1 billion in September 2025. A press release detailing these results and the leadership transition was furnished as Exhibit 99.2.
Profitelligence Alerts
Get alerts for COO
Be first to know when The Cooper Companies Inc. files with the SEC.
Filing Categories
Advertisement
About The Cooper Companies Inc.
The Cooper Companies Inc. is a global healthcare company that specializes in the production of medical devices, prominently focusing on contact lenses and women's health products. As a key player in the healthcare market, Cooper Companies owns two primary business units: CooperVision and CooperSurgical. CooperVision is renowned for its comprehensive range of soft contact lenses, catering to various vision correction needs such as astigmatism, presbyopia, and myopia control. Meanwhile, CooperSurgical provides innovative products and services focused on women's health, from fertility and lab solutions to surgical tools for gynecological procedures. This diversified business model allows Cooper Companies to impact multiple facets of the healthcare industry, supporting healthcare professionals and enhancing patient care. Headquartered in San Ramon, California, The Cooper Companies is significant in advancing optical technologies and essential medical devices, exemplifying growth within the global healthcare and medical device sectors.
Official SEC Documents
Advertisement